Latest / Pharmacy Podcast Network / The Diabetes Episode | Geriatric Pharmacy Focus
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession.
- 0:10Speaker 2: Welcome to the Pharmacy Podcast Network.
- 0:28Speaker 1: We have an aging population taking more medications than ever before.
- 0:32Speaker 1: On this podcast, I will interview experts in geriatric medicine
- 0:35Speaker 1: to gain insights so we can provide optimal care to
- 0:38Speaker 1: patients in their golden ears. I'm your host, doctor Tammar Ruggles,
- 0:41Speaker 1: and this is the Geriatric Pharmacy Focus.
- 0:47Speaker 3: Hello and welcome back to the Geriatric Pharmacy Focus. I am
- 0:50Speaker 3: your host, doctor Tamar Ruggles, and with me today is
- 0:53Speaker 3: the diabetes pharmacist, doctor Diana Isaacs. She is a pharmacist
- 0:57Speaker 3: at the Cleveland Clinic. She's a diabetes pharmacy advocate and speaker.
- 1:01Speaker 3: She is host of the Diabetes Dialogue podcast, which you
- 1:04Speaker 3: definitely need to tune into, and she is passionate about
- 1:07Speaker 3: the use of the latest technology to improve patient life.
- 1:10Speaker 3: So welcome Diana. If you could tell us a bit
- 1:13Speaker 3: about yourself and how you became the diabetes pharmacist.
- 1:16Speaker 2: Great, well, thank you so much for having me today.
- 1:19Speaker 4: So gosh, I think it all started in pharmacy school
- 1:23Speaker 4: when I was learning about diabetes from my amazing faculty
- 1:27Speaker 4: and just immediately kind of fell in love with it.
- 1:29Speaker 4: And then I was a part of APHA and the
- 1:32Speaker 4: Operation Diabetes, and we would do these health faars where
- 1:36Speaker 4: even as a student with my limited knowledge, I felt
- 1:39Speaker 4: like I could make such a difference doing glucose testing
- 1:43Speaker 4: and providing education at these health fares that I kind
- 1:46Speaker 4: of knew I just really wanted to go that path,
- 1:49Speaker 4: and so I did residency at the VA, and I
- 1:53Speaker 4: obtained my first position working as a VA pharmacist and
- 1:57Speaker 4: in academia, and got my hours for the CD which
- 2:02Speaker 4: is now CDCEES and all of that stuff.
- 2:05Speaker 2: And then when I joined Cleveland Clinic.
- 2:08Speaker 4: It's been about nine years now, they were looking for
- 2:12Speaker 4: someone that had, you know, could do type one diabetes management,
- 2:18Speaker 4: and prior to that, a lot of my you know
- 2:20Speaker 4: working was in people with type two diabetes, especially within
- 2:23Speaker 4: the VA.
- 2:23Speaker 2: So I said, no problem, let me learn immediately.
- 2:27Speaker 4: You know, there were opportunities to do a lot with
- 2:30Speaker 4: CGM and insulin pumps, so I did everything I could
- 2:33Speaker 4: to learn all about it, become a pump trainer, starts
- 2:36Speaker 4: CGM programs, and in doing it, I just realized I
- 2:41Speaker 4: loved it.
- 2:42Speaker 2: I mean I think secretly I always loved it.
- 2:45Speaker 4: I remember like if there was always that person in
- 2:47Speaker 4: class that had type one diabetes, had the insulin pump,
- 2:49Speaker 4: and I was like, Ooh.
- 2:50Speaker 2: I want to see that. I want to learn more
- 2:52Speaker 2: about it.
- 2:52Speaker 4: But there just weren't so many opportunities until I came
- 2:55Speaker 4: to Cleveland Clinic and so I just now I am
- 2:58Speaker 4: so immersed in it and just like I just I
- 3:02Speaker 4: love it so much.
- 3:03Speaker 2: And I guess that's how I became me.
- 3:06Speaker 3: I love it. Yes, follow your passion, and you'll set
- 3:09Speaker 3: the world on fire. For sure. I feel that same
- 3:11Speaker 3: way about geriatrics. That's how I felt about it in
- 3:14Speaker 3: pharmacy school. I just fell in love with our older
- 3:16Speaker 3: adults and so it's awesome to see someone that's so
- 3:19Speaker 3: passionate about it. So, as we all know, the American
- 3:22Speaker 3: Diabetes Association twenty twenty five Standards of Diabetes Care has
- 3:26Speaker 3: come out, and today we're going to focus more on
- 3:28Speaker 3: type two diabetes because that's a majority of what we
- 3:30Speaker 3: see in our older adults, especially in long term care.
- 3:34Speaker 3: And so when we talk about those EIGHTA guidelines, you know,
- 3:37Speaker 3: what are our glycemic goals for our older adults?
- 3:41Speaker 4: Yeah, so we definitely have more relaxed goals.
- 3:45Speaker 2: For older adults, we worry about the.
- 3:47Speaker 4: Risk of hypobicemia balls and so we can be more relaxed.
- 3:53Speaker 4: But I think it also depends on a lot of factors.
- 3:56Speaker 4: So it depends how long someone's had diet, what medications
- 4:02Speaker 4: they need to get to goal. If somebody is more
- 4:07Speaker 4: newly diagnosed, despite being an older adult, we don't necessarily
- 4:12Speaker 4: have to have a higher A and C goal Versus
- 4:15Speaker 4: someone that's had long standing type two diabetes that likely
- 4:19Speaker 4: it has progressed to needing more medications and may be
- 4:22Speaker 4: needing insulin. That's where we will say, you know what,
- 4:26Speaker 4: instead of needing to shoot for an A and C
- 4:28Speaker 4: of less than six point five or seven percent, let's
- 4:31Speaker 4: go ahead and aim for closer to, like less.
- 4:34Speaker 2: Than eight percent.
- 4:36Speaker 4: And if someone's more towards end of life at that point,
- 4:39Speaker 4: we may get rid of A and C goals. We
- 4:41Speaker 4: may say, you know what the priority is. We don't
- 4:44Speaker 4: want hyperglycemia. We don't want severe hyperglycemia because that can
- 4:48Speaker 4: lead to dehydration and other complications as well.
- 4:51Speaker 2: But it's not so important.
- 4:52Speaker 4: To be monitoring and getting to a specific A and
- 4:55Speaker 4: C goal. I also just want to mention, being that
- 4:59Speaker 4: I love technolog and we have a lot more CGM
- 5:02Speaker 4: used that a corresponding goal with CGM is if we're
- 5:06Speaker 4: aiming for that A and C of less than seven percent,
- 5:09Speaker 4: that's about seventy percent time in range between seventy and
- 5:12Speaker 4: one eighty.
- 5:14Speaker 2: If we are.
- 5:14Speaker 4: Aiming for that higher A one C goal of less
- 5:17Speaker 4: than eight percent, that corresponds pretty well to fifty percent
- 5:21Speaker 4: or more in that range.
- 5:24Speaker 3: Yeah, you bring up a good point about how important
- 5:26Speaker 3: it is to avoid hypoglycemia in our older adults. And
- 5:30Speaker 3: when we talk hypoglycemia, of course the red flag is
- 5:33Speaker 3: soul funnel your eas But also I did want to ask,
- 5:38Speaker 3: is there ever a time when sliding scale insulin is
- 5:42Speaker 3: appropriate for our older adults?
- 5:45Speaker 4: So yeah, so you bring up excellent points. Sulfona, yourreeas
- 5:49Speaker 4: have really really fallen out of favor. Even though they
- 5:52Speaker 4: can be effective at glucose lowering, they are much less
- 5:55Speaker 4: predictable and if someone skips a meal, that can lead
- 5:59Speaker 4: to you know, hype boat glycemia. In terms of sliding
- 6:03Speaker 4: scale insulin, so we generally don't love sliding scale insulin
- 6:08Speaker 4: because it's more of a reactive approach, so we'd prefer
- 6:11Speaker 4: to have if we need to use insulin to have
- 6:13Speaker 4: more set doses. But it is common that we may
- 6:17Speaker 4: give someone a correction scale to use.
- 6:19Speaker 2: If they are.
- 6:20Speaker 4: Requiring meal time insulin and their glucose is above target
- 6:24Speaker 4: going into their meal, we may give them a correction
- 6:28Speaker 4: scale that says they can add a certain amount of
- 6:30Speaker 4: insulin to their usual dose.
- 6:32Speaker 2: To help correct that high glucose level.
- 6:36Speaker 3: So it's okay if like looking at one of my
- 6:39Speaker 3: long term care patients, let's say, if they're on you know,
- 6:43Speaker 3: five units with meals plus sliding scale, that won't be
- 6:47Speaker 3: as much of a problem to you as maybe just
- 6:50Speaker 3: a person that's on a basal insulin plus a sliding
- 6:53Speaker 3: scale NovoLog or something like.
- 6:55Speaker 2: That, Right.
- 6:56Speaker 4: I mean the thing is, if someone is needing to
- 6:59Speaker 4: constantly add to their dose, then you want to evaluate
- 7:03Speaker 4: is something wrong with the dose it like, do we
- 7:06Speaker 4: need to go up a little bit on the long
- 7:08Speaker 4: acting insulin? Do we need to adjust the meal time
- 7:11Speaker 4: insulin at the previous meal?
- 7:13Speaker 2: So it shouldn't be something that we need to rely
- 7:15Speaker 2: so heavily on.
- 7:18Speaker 4: But I think it's a nice tool to have in
- 7:19Speaker 4: the toolbox because there. It could be somebody had an
- 7:22Speaker 4: extra snack in between meals or is just running a
- 7:26Speaker 4: little higher, and you know, if you just give the
- 7:29Speaker 4: usual dose, they're probably going to continue to run higher. Now,
- 7:33Speaker 4: with these scales, there is the risk of being used
- 7:38Speaker 4: incorrectly that you know, it is requiring some extra math.
- 7:42Speaker 4: So if someone is managing this on their own and
- 7:45Speaker 4: having to add these numbers together, that can get confusing.
- 7:48Speaker 4: There's more risk for errors that someone could end up
- 7:51Speaker 4: giving too much and then have hypot by stemia. So
- 7:54Speaker 4: I think it's you've got to evaluate all of that
- 7:57Speaker 4: and individualize. If you don't think it's going to be safe,
- 8:00Speaker 4: that the person is gonna you know, just it's going
- 8:03Speaker 4: to be too complicated, or the person's going to end up.
- 8:05Speaker 2: Over like over calculating and giving.
- 8:08Speaker 4: Too much, or the other concern we worry a lot
- 8:11Speaker 4: about is that people use these scales in between their meals.
- 8:16Speaker 4: And generally, for someone on injections, even with rapid acting insulin,
- 8:21Speaker 4: we advise to separate the doses by four hours or
- 8:25Speaker 4: more because we don't want snacking of insulin where oh,
- 8:29Speaker 4: they see they're high and they want to follow their
- 8:32Speaker 4: scale and give so many units, but really that insulin
- 8:36Speaker 4: that they gave a couple hours ago is still working
- 8:38Speaker 4: in the body, so that can be super dangerous. We
- 8:41Speaker 4: see that happen leading to hypoglycemia. So it's it's also
- 8:45Speaker 4: the person needs instructions of when to give it, and
- 8:48Speaker 4: often giving it in alignment with the meals can be
- 8:52Speaker 4: a safe way because then usually it's going to.
- 8:54Speaker 2: Be separated by four hours or more.
- 8:56Speaker 3: Yeah, yeah, okay, well that makes sense. So how about
- 9:00Speaker 3: going back to the sulfon ureas. What would you do if,
- 9:03Speaker 3: let's say a seventy eight year old patient in your
- 9:06Speaker 3: nursing home was strictly managed on glip aside five daily
- 9:10Speaker 3: and her A one cus seven point eight do you
- 9:12Speaker 3: look at the risk of that sulfona aurea and say
- 9:15Speaker 3: let's stop that and start something different, Or if they
- 9:18Speaker 3: have been maintained on that, are you less likely to
- 9:22Speaker 3: touch it?
- 9:24Speaker 4: So I think there's so many reasons to be on
- 9:27Speaker 4: other medications, and unfortunately there's a lot of clinical inertia
- 9:32Speaker 4: where you see, okay, her A one c's under eight percent,
- 9:35Speaker 4: she's not having hypoglycemia least we don't think so.
- 9:38Speaker 2: And let's just carry on.
- 9:40Speaker 4: Now, this is where CGM can be very revealing too,
- 9:43Speaker 4: because sometimes you think everything's fine, there's no hypoglycemia, but
- 9:47Speaker 4: you put a CGM on someone and you discover there
- 9:49Speaker 4: actually is some occurring during the day or overnight. Someone
- 9:53Speaker 4: that's seventy eight could have other complications, certainly could benefit
- 9:58Speaker 4: from the cardiovascular risk protection, the kidney protection of GLP
- 10:04Speaker 4: one agnis and SGLT two inhibitors.
- 10:07Speaker 2: So I really would be pushing to.
- 10:09Speaker 4: See if we could be using one of those agents instead.
- 10:14Speaker 4: And I just I mean, I would prefer to use
- 10:16Speaker 4: almost anything else that doesn't have the risk of hypoglycemia.
- 10:21Speaker 4: And even if she's not having hypoglycemia, now a lot
- 10:24Speaker 4: of things can change. What if her kidney function rapidly
- 10:27Speaker 4: deteriorates and now that sulfona aria is lasting in her
- 10:30Speaker 4: system longer. So I just they make me so uncomfortable,
- 10:34Speaker 4: especially in someone older.
- 10:35Speaker 2: So yes, we need to change it.
- 10:38Speaker 3: Yeah, I agree with you completely. I leave a lot
- 10:40Speaker 3: of notes for providers on the use of sulfona aureas
- 10:44Speaker 3: and switching to something with a more of a benefit
- 10:47Speaker 3: and then less risk. So I'm happy to hear that
- 10:50Speaker 3: you agree with that, because some.
- 10:51Speaker 2: People you're in alignment.
- 10:53Speaker 3: Yes, because sometimes the providers will write on my notes
- 10:56Speaker 3: and say doing well, no hypoglycemia noted, continue, you know,
- 11:00Speaker 3: And so that's why I kind of wanted your argument
- 11:03Speaker 3: or your perspective about it. So you talk about the
- 11:06Speaker 3: GLP ones and the SGLT two inhibitors, and reading through
- 11:09Speaker 3: the Standards of Care the twenty twenty five from the
- 11:11Speaker 3: eighty eight, it does seem like the scales have shifted
- 11:14Speaker 3: toward the GLP ones and the SGLT twos and may
- 11:17Speaker 3: be less favorable or not as much mentioned as like
- 11:20Speaker 3: the DVP fours and other medications. So can you just
- 11:23Speaker 3: briefly summarize for people who haven't read the Standards of
- 11:27Speaker 3: Care twenty twenty five our treatment for type two diabetes?
- 11:32Speaker 2: Sure? So yeah, I love the Standards of Care.
- 11:37Speaker 4: I had like the great fortune of being on the
- 11:39Speaker 4: committee that revises them back in twenty twenty to twenty
- 11:43Speaker 4: twenty three, so I just like, I love them.
- 11:45Speaker 2: I'm a geek with them.
- 11:47Speaker 4: But essentially the algorithm is separated into two major parts
- 11:52Speaker 4: that I like to think about it. The first is
- 11:53Speaker 4: you ask does the person have kidney disease, do they
- 11:58Speaker 4: have heart failure, do they have cardio vascular disease or
- 12:01Speaker 4: high risk of cardiovascular disease, and if so, you want
- 12:06Speaker 4: to use the therapy that is proven for that condition,
- 12:09Speaker 4: irrespective of what the A one C level is, because
- 12:13Speaker 4: those therapies will cause benefits. And those therapies are the
- 12:17Speaker 4: GLP one agonists and the SGLT two inhibitors. For heart failure,
- 12:21Speaker 4: it's specifically SGLT two inhibitors unless the person has obesity
- 12:26Speaker 4: antipe two diabetes, in which case the magnetide showed benefit
- 12:30Speaker 4: with hepeth. Now on the other side of the algorithm,
- 12:35Speaker 4: if someone doesn't have those conditions, then we're really looking
- 12:39Speaker 4: for one of two things. One is thinking about how
- 12:42Speaker 4: much glucose lowering do we need and selecting an agent
- 12:46Speaker 4: that will get us to that goal. And it lists
- 12:49Speaker 4: out in a hierarchy of what are the most potent
- 12:52Speaker 4: agents down to agents that may have a little bit
- 12:56Speaker 4: less glucose lowering. So the GLP one agonists are our
- 13:01Speaker 4: most ponent agents. Specifically, the maglatide, turs epetite, the high
- 13:05Speaker 4: dose dula glue tide are called out, and then as
- 13:08Speaker 4: you go further down you get into like SGLT two
- 13:11Speaker 4: inhibitors have a little bit less met Foremans a little
- 13:13Speaker 4: less and DPP four inhibitors have a little bit less. Now,
- 13:18Speaker 4: the other component of that is does your patient need
- 13:21Speaker 4: to lose weight and lower glucose, And actually ninety percent
- 13:25Speaker 4: of people with diabetes have overweight or obesity, so often
- 13:30Speaker 4: patients do benefit from both of those, in which case,
- 13:33Speaker 4: again the GLP ones are highlighted, is specifically calling out
- 13:36Speaker 4: turs appetite and some maglatide. And then it goes down
- 13:40Speaker 4: kind of choosing agents that still will have some weight loss,
- 13:43Speaker 4: like the other GLP ones. SGLT two inhibitors have a
- 13:46Speaker 4: little bit of weight loss, met Foreman's more neutral, maybe
- 13:50Speaker 4: a little tiny bit of weight loss, and then DPB
- 13:53Speaker 4: four inhibitors are very neutral. And then you'd want to
- 13:55Speaker 4: avoid agents that can cause weight gain like sulfony rheas
- 13:59Speaker 4: or in Now, in the case of an older adult,
- 14:03Speaker 4: you really got to evaluate maybe your older adult doesn't
- 14:05Speaker 4: need to lose weight, right, Like, maybe you're concerned that
- 14:08Speaker 4: they're going to become too frail, in which case you
- 14:11Speaker 4: might not want to use an agent that causes a
- 14:14Speaker 4: lot of weight loss. And so the reason why DPP
- 14:18Speaker 4: four inhibitors have fallen out of favor a little bit
- 14:20Speaker 4: is because they don't have this positive cardiovascular outcome data
- 14:25Speaker 4: that we have seen with the GLP one agonists and
- 14:27Speaker 4: SGLT two inhibitors.
- 14:29Speaker 2: For the most part, they have been very neutral.
- 14:33Speaker 4: There have been in some cases with sacks of gliptin
- 14:36Speaker 4: and alogliptin showing that there may be increased heart failure hospitalization.
- 14:41Speaker 4: So that's obviously a little bit concerning with those specific
- 14:44Speaker 4: two agents. So that's kind of why they've fallen out
- 14:48Speaker 4: of favor. But that being said, if you only need
- 14:50Speaker 4: a little bit of a one C lowering and you're
- 14:53Speaker 4: looking for an agent that isn't going to cause weight
- 14:56Speaker 4: loss and not have so many expected side effects, there
- 15:00Speaker 4: still can be a great reason to go ahead and
- 15:02Speaker 4: use those agents. And then, oh, one other thing that
- 15:05Speaker 4: I want to call out that is really new for
- 15:08Speaker 4: twenty twenty five is now looking at match so looking
- 15:12Speaker 4: at at metabolic associated the atotic liver disease. That's been
- 15:18Speaker 4: called out because we see that there's such a close
- 15:21Speaker 4: link with that and type two diabetes, and so if
- 15:25Speaker 4: someone has that, you'd want to go ahead and use
- 15:28Speaker 4: agents that are protective that will derive benefit. And so
- 15:33Speaker 4: specifically it calls out GLP one agonists have some pretty
- 15:37Speaker 4: good data around them. Also, SGLT two inhibitors have a
- 15:42Speaker 4: little bit of data and pioglittozoone specifically has shown benefit
- 15:47Speaker 4: for that condition.
- 15:49Speaker 3: Yeah, pileog litozomes making a comeback. I feel like reading through,
- 15:53Speaker 3: reading through the guidelines, I'm more and more liking pileglitizom
- 15:58Speaker 3: lately after up a little bit. And it does state,
- 16:02Speaker 3: you know, for MASH or those at high risk for
- 16:04Speaker 3: liver fibrosis, it says, how would we know if our
- 16:07Speaker 3: patient is at high risk for liver fibrosis? Would you
- 16:10Speaker 3: see an increase in those LFTs And that would kind
- 16:12Speaker 3: of alert you to maybe we should look at this.
- 16:16Speaker 2: So it's a great question.
- 16:18Speaker 4: So certainly, yes, if someone's liver function tests are elevated,
- 16:21Speaker 4: that might clue you in for a referral. But there's
- 16:24Speaker 4: actually another test that can be done that's called the
- 16:26Speaker 4: FIB four and that's a really easy test to do.
- 16:30Speaker 4: It incorporates it's a calculation that incorporates the LFTs along
- 16:35Speaker 4: with the platelet function as well, and it derives a score.
- 16:39Speaker 2: And so if the score is.
- 16:41Speaker 4: Elevated, then that prompts you that actually to do some
- 16:45Speaker 4: imaging to check to see if there is a fiber
- 16:49Speaker 4: scan that they're supposed to do, which will determine basically
- 16:53Speaker 4: if they have mash or mass hold, and then that
- 16:57Speaker 4: can guide you in terms of if they.
- 16:59Speaker 2: Need a referral to Gee.
- 17:00Speaker 3: Okay, yeah, that's helpful reading about pioglitazone and correct me
- 17:06Speaker 3: if I'm wrong. Is it one of the few agents
- 17:08Speaker 3: we have that can actually decrease insulin resistance?
- 17:12Speaker 4: It is, so it does decrease insulin resistance. It does
- 17:18Speaker 4: so in a more direct way versus other agents have
- 17:20Speaker 4: a more indirect function and reducing insulin resistance. But yes,
- 17:25Speaker 4: I've heard it described like exercise in a pill, because.
- 17:29Speaker 2: That's what exercise does.
- 17:31Speaker 4: It basically makes the muscles, the cells more sensitive to
- 17:34Speaker 4: insulin and allows the glucose to be taken into these cells.
- 17:38Speaker 4: So pioglidozoone has that great, great benefit, and it's actually
- 17:43Speaker 4: it's taking the fat from the places we don't want
- 17:47Speaker 4: the fat, like the liver, and putting the fat in
- 17:49Speaker 4: the places.
- 17:50Speaker 2: That it should be. So that is a great mechanism.
- 17:54Speaker 4: Now, it does typically cause some weight gain, so that's
- 17:58Speaker 4: one of the reasons why it's a little bit you know,
- 18:01Speaker 4: it may not be our first choice medication. But now
- 18:05Speaker 4: that we're seeing all these these other benefits, it is
- 18:08Speaker 4: often a great kind of agent to use.
- 18:13Speaker 3: Yeah. And one thing if patients are maybe hesitant to
- 18:17Speaker 3: use it because of the weight gain or even it
- 18:19Speaker 3: got a bad wrap, you know with heart failure with
- 18:22Speaker 3: the rosaklitosone. But I think one thing to think about
- 18:25Speaker 3: is is some of that waking from the fat redistribution
- 18:30Speaker 3: from visceral to SubQ And if so, maybe that's not
- 18:33Speaker 3: such a bad thing. I don't know what are your
- 18:35Speaker 3: thoughts on that.
- 18:36Speaker 4: Well, you're exactly right, like it's not like wa gain
- 18:40Speaker 4: associated with just eating more food.
- 18:44Speaker 2: I think it's a healthier type of we gain.
- 18:47Speaker 4: And the thing is not all weight is the same,
- 18:51Speaker 4: So I think this is a much healthier type of
- 18:53Speaker 4: weight gain. So that you know it's a positive effect.
- 18:57Speaker 4: It's just unfortunately we're all often looking at weight in
- 19:01Speaker 4: such a simplistic way. We're just looking at the pounds
- 19:03Speaker 4: on the scale, and so it can seem like it's
- 19:08Speaker 4: a negative thing, when actuality it can be a positive thing.
- 19:12Speaker 4: There is also though there's some concern in people that
- 19:15Speaker 4: have osteoporosis that there can be more bone fractures, so
- 19:18Speaker 4: sometimes that's another limiting factor, especially for the older population
- 19:24Speaker 4: that we have to worry about, and then we don't
- 19:26Speaker 4: want to use it in people with heart failure, so
- 19:29Speaker 4: that's kind of another consideration, and you're absolutely right. Unfortunately,
- 19:32Speaker 4: they got a very bad rap because of rosy gletozone.
- 19:36Speaker 4: That was a meta analysis by Steve Nisson who's at
- 19:39Speaker 4: the Cleveland Clinic that show there was increased rates of
- 19:42Speaker 4: MI with use, and in the end it kind of
- 19:46Speaker 4: got debunked that it was you know, there may not
- 19:49Speaker 4: have actually been increased mis But the really positive thing
- 19:54Speaker 4: about all of this is that was really the impetus
- 19:56Speaker 4: to say, Okay, these diabetes drugs need to have cardiovavascular
- 20:00Speaker 4: outcome trials.
- 20:01Speaker 2: We can't say, oh, just because it.
- 20:04Speaker 4: Lowered a one C that it's good, because maybe it's
- 20:08Speaker 4: not good if it's causing heart attacks. So it's really
- 20:12Speaker 4: because of that that we now have all of this
- 20:15Speaker 4: rich data with the GLP one agonists and the SGLT
- 20:18Speaker 4: two inhibitors, and we've learned that they're not just safe,
- 20:24Speaker 4: but they're so beneficial for reducing these cardiovascular outcomes. And
- 20:29Speaker 4: the other thing is, had we not done this, we
- 20:32Speaker 4: might actually still be using DP before inhibitors a whole
- 20:35Speaker 4: lot more because we also would know that those are
- 20:37Speaker 4: neutral compared to the others, and with all the things
- 20:40Speaker 4: being the same, like I would want to use a
- 20:42Speaker 4: drug that lowers the cardiovascular risk, right, but if we
- 20:45Speaker 4: didn't have this data, we want to have known that.
- 20:47Speaker 4: And so that's some of the history and how it's
- 20:50Speaker 4: led to where we are now.
- 20:52Speaker 3: Yeah, such a good point because we have like I
- 20:55Speaker 3: even think about lipid lowering medications when you look at niosin, Yeah,
- 20:58Speaker 3: does it benefit nearly every aspect of the lipid panel. Absolutely,
- 21:02Speaker 3: But is it gonna lower you risk of major curreer
- 21:05Speaker 3: of mass events? Well not probably not so so Yeah,
- 21:08Speaker 3: there's drugs on the market that will do what maybe
- 21:11Speaker 3: you want it to do in lowering A and C.
- 21:14Speaker 3: But if it's not going to give you long term benefit,
- 21:16Speaker 3: let's let's switch to something that will lower urency and
- 21:19Speaker 3: give you long term benefits.
- 21:21Speaker 4: Right. New data is awesome, right, Yeah, And you bring
- 21:25Speaker 4: such a blast from the past because back when I
- 21:27Speaker 4: used to work in the VA system, that was like
- 21:29Speaker 4: when NYA sin was a thing, like we.
- 21:31Speaker 2: Were using it. We were like, yeah, we're going to
- 21:33Speaker 2: raise your HDM. We're going to lower your tryglys rides.
- 21:36Speaker 2: We'll add it to our statin like it was big.
- 21:39Speaker 2: We're putting everyone on it.
- 21:40Speaker 4: And then now that we know it doesn't do anything
- 21:44Speaker 4: to improve out out really and it causes flushing, it's
- 21:47Speaker 4: really fallen out of favor.
- 21:50Speaker 3: Yes, oh, I love clinical trials. So we have all
- 21:53Speaker 3: this data, So okay, so let's go through some scenarios.
- 21:56Speaker 3: I wrote up some scenarios of older adults that is
- 21:59Speaker 3: probably typical that we would see, and let's just talk
- 22:02Speaker 3: through what might be appropriate, what might be A one
- 22:04Speaker 3: C goals, et cetera. So first, this is someone I
- 22:07Speaker 3: see often and I'm really curious your opinion on this.
- 22:10Speaker 3: So let's say we have Edward. He's seventy two year
- 22:12Speaker 3: old male and he has pre diabetes. So his A
- 22:15Speaker 3: one C has been teetering between six point two and
- 22:17Speaker 3: six point three for a couple of years now. He
- 22:20Speaker 3: put a CGM on for fourteen days, kind of saw
- 22:23Speaker 3: what triggered his blood sugar. Has made some dietary.
- 22:26Speaker 2: Changes, got his A one C down to maybe you.
- 22:29Speaker 3: Know, six point one six point zero, but hasn't been
- 22:31Speaker 3: able to get out of that pre diabetes range. What
- 22:34Speaker 3: do you do with this man? Do you do you
- 22:36Speaker 3: start therapy to prevent you know, full blown diabetes diagnosis
- 22:41Speaker 3: or do you just let him keep teetering along?
- 22:44Speaker 4: Well?
- 22:44Speaker 2: Does he have obesity?
- 22:46Speaker 3: Also, let's say he could lose mild mild. Let's say
- 22:50Speaker 3: he goes ten pounds but nothing crazy.
- 22:53Speaker 2: Yeah, so.
- 22:55Speaker 4: If he does, if he has weight to lose, it
- 22:58Speaker 4: sounds like he only has ten pounds to lose, then
- 23:01Speaker 4: he may not qualify for needing to treat his weight.
- 23:05Speaker 4: If he did, then I would say that could be
- 23:07Speaker 4: a great approach to try to lower his weight. I
- 23:10Speaker 4: don't know that we have to really do anything in
- 23:12Speaker 4: this case other than continuing to reinforce healthy behavior changes.
- 23:18Speaker 2: Yes, I mean technically met foreman can be an option.
- 23:21Speaker 4: We can use that for pre diabetes, and that may
- 23:24Speaker 4: help to delay the progression to type two diabetes.
- 23:27Speaker 2: So I would bring it up through shared decision.
- 23:29Speaker 4: Making, also taking a look at his kidney function, everything else,
- 23:34Speaker 4: and see what he would like to do. The truth is,
- 23:37Speaker 4: even having pre diabetes is a cardiovascular risk factor, and
- 23:42Speaker 4: so there could be some benefit to lowering it further.
- 23:46Speaker 4: So I think that it really would be done through
- 23:48Speaker 4: shared decision making talking about some of these you know,
- 23:51Speaker 4: benefits and risks.
- 23:53Speaker 2: The truth is, if.
- 23:54Speaker 4: He had full blown type two diabetes, we'd be very
- 23:56Speaker 4: happy with his A one C, right. So I don't
- 23:59Speaker 4: know that we have to push it and say you
- 24:02Speaker 4: we need to get you on met foreman, or we
- 24:04Speaker 4: need to put you on a GLP one, right, But
- 24:06Speaker 4: I think that it's good for him to know it's
- 24:08Speaker 4: an option, and if he is really motivated and he
- 24:11Speaker 4: wants to do that, we can. And met Forma does
- 24:13Speaker 4: not cause hypoglycemia, I would probably lean much heavily to
- 24:17Speaker 4: met foreman because if he is not he doesn't have
- 24:20Speaker 4: a BMI over thirty, I'm probably not gonna even try,
- 24:24Speaker 4: and probably we won't get the GLP one covered anyway.
- 24:27Speaker 3: But if his BMI was over thirty, then a GLP
- 24:30Speaker 3: one would be a good option.
- 24:31Speaker 4: Well, yeah, I think there's there's certainly benefit to losing weight,
- 24:34Speaker 4: and that would likely you know, that's going to reduce
- 24:37Speaker 4: his cardiovascular risk, that's gonna get his A one C down,
- 24:41Speaker 4: gonna facilitate.
- 24:42Speaker 2: Weight loss, which will have a lot of other benefits too.
- 24:44Speaker 4: So absolutely, if his BMI was over thirty, I would
- 24:48Speaker 4: bring that up, it's just going to be the whole
- 24:49Speaker 4: thing with coverage.
- 24:51Speaker 3: Sure, Okay, so that was Edward. Now let's talk about Betsy.
- 24:55Speaker 3: Let's say Betsy's seventy eight year old female. She has
- 24:59Speaker 3: type two diabetes, use hypertension, hyperlipidemia, and asthma. So she's
- 25:02Speaker 3: got a few different comorbid conditions. But she's pretty active,
- 25:06Speaker 3: and she was in her own home until she fell
- 25:08Speaker 3: and broke her hip. Now she's just in a nursing
- 25:10Speaker 3: home rehabit and then hoping to go right back home.
- 25:13Speaker 3: So what would her A one C goal be and
- 25:15Speaker 3: what do you think an appropriate treatment regiment would look
- 25:18Speaker 3: like for her?
- 25:19Speaker 4: So definitely we can have a higher A one C
- 25:23Speaker 4: goal because of her fall risk and everything, although it
- 25:27Speaker 4: still depends on the medications of person is taking. Because
- 25:32Speaker 4: if let's say she's on like a GLP one and
- 25:37Speaker 4: we can get her to a lower A one C
- 25:40Speaker 4: and we could do that safely, I have no issue
- 25:44Speaker 4: with it. But I would say I think an A
- 25:46Speaker 4: one C goal of less than eight percent would be
- 25:49Speaker 4: completely fine, especially if she's needing she's needing insulin. Definitely,
- 25:54Speaker 4: I think that that higher A one C goal is
- 25:56Speaker 4: where we go. It's just that where where I struggle
- 26:00Speaker 4: is when we set these higher A one s goals
- 26:03Speaker 4: and we have patients that are on very minimal therapy,
- 26:07Speaker 4: Like let's say she's on just a DPP four inhibitor.
- 26:12Speaker 4: Let's say she's on like five hundred billigrams of met
- 26:14Speaker 4: format and she has normal kidney function. I mean, why
- 26:18Speaker 4: do we have to say, oh, well, let's just get
- 26:21Speaker 4: her a one seed to seven point eight seven point
- 26:22Speaker 4: nine and call it a day. So I think that's
- 26:25Speaker 4: where we have to look and say, well, if we
- 26:28Speaker 4: can safely do this, then like why not do it?
- 26:31Speaker 4: Like she could have an AEC of six point five
- 26:33Speaker 4: if she doesn't need therapies that cause side effects and
- 26:36Speaker 4: cause hypoglycemia, she can go lower than that. But I
- 26:38Speaker 4: would say less than eight would be the starting place.
- 26:43Speaker 3: Yeah. I like that mindset because yeah, it's not like
- 26:48Speaker 3: it would cause harm to probably go from a met
- 26:51Speaker 3: form at yard also five hundred to one thousand, and
- 26:53Speaker 3: for kidney functions good. It might bring her a one
- 26:56Speaker 3: seat down a little more and prevent some macro or
- 26:58Speaker 3: microvascular complications without causing her any harm. So I think
- 27:03Speaker 3: that's that's a good way of looking at it like, yeah,
- 27:05Speaker 3: our goal is less than eight, but that doesn't mean
- 27:07Speaker 3: we're not going to optimize medications.
- 27:11Speaker 2: Right, That's where I think we just really have to
- 27:13Speaker 2: individualize it.
- 27:15Speaker 3: Okay, I like that. Okay, so let's move on to
- 27:18Speaker 3: the next person. Maybe we have Okay, so let's talk
- 27:20Speaker 3: about Robert. He's eighty five, he's got multiple complex disease dates,
- 27:25Speaker 3: type two diabetes, hypertension, hyperlipide, man Parkinson disease, and he's
- 27:29Speaker 3: a long term stay in a nursing home. But he's
- 27:32Speaker 3: not at the end of his life yet.
- 27:33Speaker 2: So what would be a.
- 27:34Speaker 3: Good a one C goal for him and then also
- 27:36Speaker 3: a treatment plan. Is he kind of similar to the
- 27:39Speaker 3: scenario before.
- 27:41Speaker 4: I think he's similar to the scenario before. I think probably.
- 27:46Speaker 2: Less than eight. It sounds like he's.
- 27:48Speaker 4: A little bit, you know, perhaps a little bit more complex.
- 27:52Speaker 4: So in his case, we may be you know, pretty
- 27:56Speaker 4: satisfied with the closer to eight, but it's also again
- 27:59Speaker 4: going to depend on the medications that he's taking and
- 28:03Speaker 4: kind of individualizing.
- 28:04Speaker 2: It from there.
- 28:05Speaker 3: Yeah.
- 28:05Speaker 4: Yeah. The other thing I think about is like, yeah,
- 28:08Speaker 4: if someone is not on medication, or they're on very
- 28:12Speaker 4: little medication, it's not like there's an A and C
- 28:15Speaker 4: that's necessarily too low.
- 28:18Speaker 2: Like the way I think.
- 28:19Speaker 4: About it is the people that are using GLP ones
- 28:22Speaker 4: for obesity and don't even have diabetes, Like, think about
- 28:26Speaker 4: how low their A and cs get, Like we don't
- 28:29Speaker 4: even routinely measure them, really, so they can be very low, right,
- 28:35Speaker 4: they can be in the fours, they can be in
- 28:36Speaker 4: the fives. So a low A and C by itself
- 28:40Speaker 4: isn't an issue. It just really depends on the medications
- 28:44Speaker 4: a person needs to get there, and so I would
- 28:48Speaker 4: make it a priority. I'm guessing with all these other comorbidities,
- 28:51Speaker 4: he's probably taking a lot of other medications, right, and
- 28:55Speaker 4: with a Parkinson's disease you can be at higher fall risk.
- 28:58Speaker 4: And so I don't think we need to be heroes
- 29:01Speaker 4: and add all these drugs to get into goal. So
- 29:06Speaker 4: you know that those are the things I would take
- 29:08Speaker 4: into consideration on that.
- 29:10Speaker 3: So do you think, let's say, for these last two patients,
- 29:13Speaker 3: their A and C is at eight, but we were
- 29:14Speaker 3: able to safely optimize medications without a high risk down
- 29:19Speaker 3: to an A and C of seven, would a patient
- 29:23Speaker 3: feel a difference as far as quality of life or
- 29:27Speaker 3: how they feel. Do you think they would feel better
- 29:31Speaker 3: and noticeably feel better from an eight to a seven?
- 29:36Speaker 2: So, in of itself, the A to a seven possibly not.
- 29:40Speaker 4: But what the missing piece is is the glucose variability.
- 29:44Speaker 4: And that's the challenge with the A and C alone
- 29:46Speaker 4: is it's based on an average. A seven is an
- 29:49Speaker 4: average of one point fifty four. But I need to
- 29:52Speaker 4: know what's happening in between that average, and that is
- 29:55Speaker 4: where CGM is also very helpful. Even if a person's
- 29:58Speaker 4: not wearing it all the time, to occasionally wear it
- 30:02Speaker 4: prior to office visits can be very revealing because what
- 30:06Speaker 4: we want to do is get rid of times of
- 30:09Speaker 4: extreme hyperglycemia because then that can be symptomatic, right, that
- 30:12Speaker 4: could be increased thirst and urination and fatigue, and we
- 30:16Speaker 4: also don't want hypoglycemia that can be falls that also
- 30:19Speaker 4: can make a person not feel good. And also people
- 30:21Speaker 4: generally don't feel good when they're bouncing around and going
- 30:23Speaker 4: from low to high and vice versa.
- 30:26Speaker 2: So it's more about that.
- 30:28Speaker 4: I think if they're having a lot of variability, they're
- 30:30Speaker 4: going to feel that with all things being equal, that no,
- 30:35Speaker 4: I mean, someone's probably not going to really know the
- 30:37Speaker 4: difference between the seven and eight based on.
- 30:40Speaker 2: Just how they're feeling.
- 30:41Speaker 4: It's not until you get to glucose levels really high
- 30:44Speaker 4: that people have symptoms. And sometimes they don't even have
- 30:48Speaker 4: symptoms then because they get used to it. So it's
- 30:52Speaker 4: more I would say about the long term, the long
- 30:56Speaker 4: term complications, And that's something to think about someone ages.
- 31:01Speaker 4: What are we trying to prevent If we're trying to
- 31:03Speaker 4: prevent a cardiovascular event ten years down the line and
- 31:05Speaker 4: they may not have ten years of life expectancy, then
- 31:08Speaker 4: kind of what are we doing?
- 31:09Speaker 2: Why do we need to get so aggressive with therapy?
- 31:12Speaker 4: Even if it doesn't cause hypoglycemia, it still could affect
- 31:15Speaker 4: other things, right, It still could affect electrolytes like possibly
- 31:18Speaker 4: kiddy function depending on the therapy, Like, so we still
- 31:22Speaker 4: need to think about that too.
- 31:24Speaker 3: Yeah, So let's say our patients are progressing now to
- 31:27Speaker 3: poor health toward end of life or even on hospice.
- 31:30Speaker 3: At that point, what do we what do we do
- 31:34Speaker 3: for our patients with type two diabetes And we know
- 31:37Speaker 3: of the A and C is no longer even a goal, right,
- 31:39Speaker 3: it's to prevent hypoglycemia and symptomatic hyperglycemia, right, But what
- 31:43Speaker 3: would a treatment plan look like for these patients that
- 31:46Speaker 3: are end of life, nearing end of life in poor health.
- 31:50Speaker 4: Yeah, so we're trying really to avoid extreme hyperglycemia dehydration,
- 31:55Speaker 4: and then we don't want any hypoglycemia either, so we're
- 32:00Speaker 4: going to want to use agents. You know, a little
- 32:04Speaker 4: bit of medication to get to goal is needed, but
- 32:08Speaker 4: not definitely not too much.
- 32:10Speaker 2: What it could look like.
- 32:11Speaker 4: I mean, it could be a once a day long
- 32:13Speaker 4: acting insulin just to get them down so they're not
- 32:17Speaker 4: having hyperglycemia. But maybe we get rid of meal time
- 32:21Speaker 4: insulin if they needed that in the past, because perhaps
- 32:24Speaker 4: appetite is not as good and it's just you know,
- 32:27Speaker 4: it's more risk than benefit if someone is having wide fluctuations.
- 32:33Speaker 2: You can add, we can add.
- 32:35Speaker 4: Like a low dose or give a dose with the
- 32:37Speaker 4: largest meal, but we really we kind of want the
- 32:40Speaker 4: minimum to get to avoid these extreme complications. But we're
- 32:47Speaker 4: not trying to get down like, we're not trying at
- 32:50Speaker 4: this point to reduce that risk of micro or macrovascular complications.
- 32:54Speaker 4: So there's not this drive to get a one ce lower,
- 32:58Speaker 4: not like a younger, healthier person.
- 33:02Speaker 3: Yeah, so maybe just a basal insulin to the to
- 33:05Speaker 3: keep the levels low enough where they want have symptomatic hyperglycemia,
- 33:09Speaker 3: but they also want to have hypoglycemia.
- 33:11Speaker 4: Right, in this case, I'd actually consider write a long
- 33:14Speaker 4: acting insulin.
- 33:15Speaker 2: And this is.
- 33:16Speaker 4: Where you might even have just a very small correction
- 33:20Speaker 4: scale for times where let's say the person really.
- 33:24Speaker 2: Had an excursion they hit three, they hit.
- 33:26Speaker 4: Four hundred or more and that's not good and you
- 33:29Speaker 4: want to bring them down and you just give them
- 33:31Speaker 4: a tiny bit of rapid acting insulin. So there does
- 33:35Speaker 4: need to be some monitoring in this situation, whether it's
- 33:38Speaker 4: BGM or CGM, but we need some kind of monitoring.
- 33:42Speaker 4: And actually there's many situations, especially like when people get
- 33:46Speaker 4: to end stage renal disease or anemia is a different
- 33:50Speaker 4: hemoglobe monopathies where A one C is not even accurate,
- 33:53Speaker 4: and it's actually very concerning when sometimes someone will have
- 33:58Speaker 4: a falsely low A one C and so the therapy
- 34:01Speaker 4: is like backed off or nobody's monitoring and like it
- 34:04Speaker 4: turns out there's actually a lot of hyperglycemia, it's just
- 34:07Speaker 4: the A and C was falsely low.
- 34:09Speaker 2: So we do need we need to be doing some
- 34:11Speaker 2: kind of monitoring.
- 34:13Speaker 3: Yeah, that's a valid point because most of my patients
- 34:17Speaker 3: have some type of anemia of chronic disease. They just
- 34:20Speaker 3: had a surgery. I mean, there's there's few who have
- 34:25Speaker 3: just like a perfect CBC, and so yeah, that's a
- 34:29Speaker 3: great point when monitoring that hemoglobin AEC if they are
- 34:32Speaker 3: an emic.
- 34:32Speaker 4: If you don't have access to like CGM, sometimes like
- 34:35Speaker 4: a frutosamine can be a secondary marker. I use it
- 34:38Speaker 4: sometimes if the AEC is like just not kind of
- 34:41Speaker 4: making sense matching up.
- 34:42Speaker 2: It's just another metric. It's less you know, it's less validated.
- 34:47Speaker 4: But it still can provide kind of a peek into
- 34:50Speaker 4: what the average glucose is.
- 34:52Speaker 3: Great, that's a great tool for us to use. So
- 34:55Speaker 3: when it comes to it's you know, cgms in long
- 34:58Speaker 3: term care is a difficult situation because you can't build
- 35:02Speaker 3: a medicare for cgms when they're in a nursing home.
- 35:05Speaker 3: So what do your patients typically do. Do you have
- 35:08Speaker 3: those families who just you know, sign and say, hey,
- 35:10Speaker 3: all pay out a pocket for this CGM. Do you
- 35:13Speaker 3: have nursing homes that are saying we see the benefit,
- 35:15Speaker 3: so we'll pick up the cost for this or what
- 35:17Speaker 3: do you see in your practice?
- 35:20Speaker 4: Yeah, so I see the families will sometimes bill pay
- 35:23Speaker 4: for it because they find that the benefit is really
- 35:26Speaker 4: worth it. And depending on the CGM you get, I
- 35:30Speaker 4: mean you can the cost has come down a lot,
- 35:34Speaker 4: and there's sometimes there's there's cubonds like with good RX
- 35:37Speaker 4: that you can get a better discount on it. So
- 35:41Speaker 4: there are families that very much say this is worth it.
- 35:44Speaker 4: Yes there's a monthly cost to it, but we are
- 35:46Speaker 4: going to go ahead.
- 35:47Speaker 2: And pay for it.
- 35:48Speaker 4: And that way the person can have CGM and not
- 35:52Speaker 4: have to poke themselves as much perhaps but also be
- 35:56Speaker 4: alerted for those highs and lows that can be happening
- 35:59Speaker 4: in between between meals and usual tracks. So there's a huge,
- 36:04Speaker 4: huge benefit. I guess we need to do some advocacy
- 36:08Speaker 4: to get them covered in these situations. But I certainly
- 36:13Speaker 4: somebody on meal time insulin like I mean to not
- 36:18Speaker 4: have CGM as substandard care, like it really is, like
- 36:22Speaker 4: it is the gold standard to have CGM, so we
- 36:25Speaker 4: just like we need to push for that to be available.
- 36:29Speaker 4: But at the same time also then the staff would
- 36:32Speaker 4: need to be comfortable with using CGM and kind of
- 36:37Speaker 4: troubleshooting the CGM as well.
- 36:39Speaker 3: Ideally, Yeah, I agree. I hope there's a lot of
- 36:43Speaker 3: advocacy and that cgms will be covered for patients in
- 36:47Speaker 3: nursing facilities by Medicare, because what an important thing for
- 36:52Speaker 3: even preventing hypo glycemia. I mean, the amount, the huge
- 36:56Speaker 3: difference this could make in our patients' lives and even
- 36:59Speaker 3: for our facility would be massive if we could just
- 37:02Speaker 3: get themcovered. So we'll definitely be advocating for that and
- 37:06Speaker 3: pushing for that. So a couple of questions that I've
- 37:09Speaker 3: thought of as we've been talking SGLT two inhibitors. You know,
- 37:13Speaker 3: our older adults can be frequent flyers when it comes
- 37:16Speaker 3: to having urinary tract infections. At what point do you say,
- 37:20Speaker 3: all right, we need to stop this SGLT two inhibitor
- 37:23Speaker 3: because the risk is greater than the benefit at this point.
- 37:26Speaker 4: Yeah, I mean we can treat the UTIs, but yeah,
- 37:30Speaker 4: at some point it's you know, you got to look
- 37:33Speaker 4: at benefit versus risk. I would take into account the
- 37:37Speaker 4: other comorbidities and what we're using it for. So if
- 37:40Speaker 4: a person has heart failure, there's definitely a much stronger
- 37:44Speaker 4: indication same with kidney disease as well.
- 37:47Speaker 2: If we're just.
- 37:48Speaker 4: Using it as a diabetes agent to lower glucose, then
- 37:51Speaker 4: I'd say, all right, let's try to use a different agent.
- 37:54Speaker 2: So I take all of that kind of into consideration.
- 37:57Speaker 4: The other thing is people are more predisposed to UTIs
- 38:00Speaker 4: when glucose levels are higher, So trying to work on
- 38:04Speaker 4: can we you know, can we get it down with
- 38:07Speaker 4: adding another agent, with doing something else to prevent that risk,
- 38:10Speaker 4: and then also just good hygiene habits can reduce that
- 38:14Speaker 4: risk as well.
- 38:16Speaker 3: Very good. Okay, last question when it comes to golp ones,
- 38:19Speaker 3: this is purely anecdotal. This, this has not been published
- 38:23Speaker 3: or any sort of the thing. But when I see
- 38:28Speaker 3: the golp ones used in my nursing own patients, I
- 38:31Speaker 3: do not see the weight loss that I see in
- 38:34Speaker 3: the community. I don't know if you've seen this, but
- 38:37Speaker 3: I'll have a patient start on some aglatide or whatever
- 38:41Speaker 3: it might be, and their weight basically stays the same,
- 38:45Speaker 3: whereas in the community setting, if they were started on
- 38:47Speaker 3: that and it was increased, they would lose massive amounts
- 38:51Speaker 3: of weight and maybe even come off their insulin. I
- 38:53Speaker 3: don't know. Is it because you know, they're the food
- 38:56Speaker 3: choices that they're offered. They don't have control over their
- 38:58Speaker 3: sedentary Have you I've seen this at all in your
- 39:02Speaker 3: practicers just me seeing it, Well.
- 39:05Speaker 2: It's really interesting.
- 39:06Speaker 4: There's for sure there's people that respond really well and
- 39:09Speaker 4: then there's people that don't respond as well. In general,
- 39:12Speaker 4: people with type two diabetes don't have as much weight
- 39:15Speaker 4: loss compared to people that are being using it just
- 39:18Speaker 4: to treat obesity.
- 39:20Speaker 2: Additionally, we know.
- 39:22Speaker 4: That when it comes to the benefits like the samaglatide
- 39:25Speaker 4: and ters eppetite will have more weight loss than others,
- 39:28Speaker 4: and it appears based on some data that trus appetite
- 39:32Speaker 4: there's more weight loss with that. So sometimes some things
- 39:35Speaker 4: will do if someone's not losing weight is we'll try
- 39:38Speaker 4: to increase the dough switch to a different one, switch
- 39:41Speaker 4: to terrs epetide, and that can help.
- 39:44Speaker 2: But I do suspect in this case that it.
- 39:46Speaker 4: Is likely related to activity level that they're just like
- 39:52Speaker 4: even if they're eating less, if they're not able to
- 39:56Speaker 4: if they're not getting up, they're not burning calories, they're
- 39:58Speaker 4: not exercising, they're not strength training, that it's just going
- 40:03Speaker 4: to be harder to lose weight, Like, yeah, there's probably
- 40:06Speaker 4: a calorie deficit a little bit, but their their metabolisms
- 40:10Speaker 4: are probably also slowing, so it's just it's.
- 40:12Speaker 2: Going to be harder to lose that weight. So that's
- 40:16Speaker 2: kind of my own, my own hypothesis on that.
- 40:21Speaker 4: But hopefully they're still at least deriving the usually they
- 40:24Speaker 4: still derive the glucose benefit even if there's not as
- 40:26Speaker 4: much of that weight loss.
- 40:28Speaker 3: Right, Yeah, that's one thing I definitely monitor for is
- 40:31Speaker 3: both weight and you know, blood glucpose regulation. What are
- 40:35Speaker 3: their sugars like, are they have they improved? Even all
- 40:38Speaker 3: the patient isn't, you know, losing weight, So there's still
- 40:41Speaker 3: benefit to being on the medication. But I do have
- 40:44Speaker 3: a nursing home patient that was started on I don't
- 40:48Speaker 3: remember if it was trizeppetite or which one, but slowly
- 40:52Speaker 3: I saw other medications being added on for constipation, right,
- 40:57Speaker 3: so it was that, But then all of a sudden
- 40:59Speaker 3: she's on lens us and then all of a sudden
- 41:01Speaker 3: raglin has started, and I'm thinking, why don't we stop
- 41:05Speaker 3: this medication? What are your thoughts on that? Do you
- 41:08Speaker 3: see that in our older adults, because we already know
- 41:11Speaker 3: they have decreased motility with aging. Are you seeing it
- 41:15Speaker 3: become a problem in older adults.
- 41:17Speaker 4: Yes, So the gi effects of GLP ones are no joke,
- 41:22Speaker 4: and they seem to older adults seem to be much
- 41:25Speaker 4: more prone to these effects. And while diarrhea gets a
- 41:29Speaker 4: lot of attention, constipation is also a pretty big effect
- 41:34Speaker 4: that can occur. Sometimes they both occur and they alternate,
- 41:37Speaker 4: which is its own challenge. I think one of the
- 41:40Speaker 4: things that contributes to it is definitely the lack of
- 41:44Speaker 4: having enough fiber rich foods and also water intake. And
- 41:48Speaker 4: sometimes what happens is the people are eating less and
- 41:52Speaker 4: then they're also drinking less and they're not having enough
- 41:56Speaker 4: They're not having enough fluids, and that can lead to
- 41:58Speaker 4: dehydration that can also, you know, worsen constipation. So yes,
- 42:04Speaker 4: I think at some point we have to ask ourselves,
- 42:07Speaker 4: if we are adding so many drugs so that someone
- 42:11Speaker 4: can tolerate this drug, is it really worth it to
- 42:14Speaker 4: continue that because all these other drugs can also have
- 42:17Speaker 4: its own host of side.
- 42:18Speaker 2: Effects, So it's really taking a step back.
- 42:23Speaker 4: My perspective on it is if I'm adding something in
- 42:26Speaker 4: the beginning to get someone to tolerate when we're first
- 42:29Speaker 4: starting the dose or we're initially going up on it.
- 42:32Speaker 4: Like I have no problem you know, giving a little
- 42:34Speaker 4: bit of zofran for example, if someone's having nausea. But
- 42:37Speaker 4: I don't want someone to need to continue all of
- 42:40Speaker 4: these other medications forever, Like that's not the goal. So
- 42:43Speaker 4: I think we really need to reevaluate. Sometimes someone will
- 42:47Speaker 4: tolerate one GLP better than another, so it could be,
- 42:52Speaker 4: you know, we try to reduce the dose, we try
- 42:54Speaker 4: to switch to a different one. But yeah, I do
- 42:57Speaker 4: not want someone to have to take all of these others.
- 42:59Speaker 4: I'd rather like fiber. Let's have fiber rich food, Let's
- 43:03Speaker 4: drink water and see how things go.
- 43:06Speaker 3: Okay, I like that. So maybe control the symptoms to
- 43:09Speaker 3: start or when you're increasing the dose, but we don't
- 43:12Speaker 3: want to have to use them long term. If we're
- 43:14Speaker 3: needing them long term, consider switching to a different Yeah, okay.
- 43:18Speaker 2: Very helpful.
- 43:19Speaker 3: Well today's been amazing. I've learned so much and I
- 43:22Speaker 3: appreciate being able to ask you these questions and learn
- 43:24Speaker 3: from you. And so if our listeners would like to
- 43:27Speaker 3: continue learning from you, where can they find you?
- 43:30Speaker 4: Oh? Yes, yes, yes, well you can find me on
- 43:32Speaker 4: all social media, So I'm Diana, I'm Isaac on X,
- 43:37Speaker 4: on Instagram, you can just look me up on LinkedIn.
- 43:42Speaker 4: But then I also have a podcast called Diabetes Dialogue, Technology,
- 43:46Speaker 4: Therapeutics and real world Perspectives. I do this with my
- 43:51Speaker 4: amazing friend and colleague Natalie Bellini, who is a nurse
- 43:54Speaker 4: practitioner also in Cleveland with me, but at a different
- 43:58Speaker 4: health system, and I kind of banter.
- 44:00Speaker 2: Back and forth and we talk about like the latest.
- 44:04Speaker 4: Data, new studies that come out, things that have happened
- 44:06Speaker 4: at professional meetings, new drug approvals for diabetes, or new technology.
- 44:12Speaker 4: So you can check that out, I believe wherever you
- 44:15Speaker 4: get your podcasts, but also if you want to see
- 44:18Speaker 4: the video versions, it's a website called hcplive dot com
- 44:23Speaker 4: and you should see a link on there for Diabetes Dialogue.
- 44:27Speaker 3: Yes, everyone go check out our podcasts because, like I
- 44:29Speaker 3: was telling Diana before we started recording, I work with
- 44:32Speaker 3: so many older adults and not a ton of them
- 44:35Speaker 3: use cgms. But I also still work part time in
- 44:37Speaker 3: a community firms each so to keep up I have
- 44:39Speaker 3: to listen. I not have to. I enjoy listening to
- 44:42Speaker 3: Diana's Podcast to stay abreast of the latest technology and
- 44:47Speaker 3: treatment for our Type ones and our Type twos that
- 44:49Speaker 3: are younger adults. So you do amazing work. Thank you
- 44:53Speaker 3: for today, and everyone go check out Diana and have
- 44:55Speaker 3: an amazing rest of your day.
- 44:57Speaker 2: Great. Thank you.